Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

8.7%

2 terminated/withdrawn out of 23 trials

Success Rate

88.2%

+1.7% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

7%

1 of 15 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
8(57.1%)
Phase 2
4(28.6%)
N/A
2(14.3%)
14Total
Phase 1(8)
Phase 2(4)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT07246486Completed

Composition of the Intestinal Microbiome in Patients With Recurrent Spontaneous Abortions.

Role: collaborator

NCT06114628Phase 2Recruiting

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Role: collaborator

NCT05727267Phase 1Recruiting

A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate

Role: collaborator

NCT04119440Phase 1Completed

Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS

Role: collaborator

NCT05051098Recruiting

A Non-interventional Registry for Patients with Hepatitis B Virus Infection

Role: collaborator

NCT03350425Completed

Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients

Role: collaborator

NCT06002802Completed

Study on Infectious Mononucleosis in Munich

Role: collaborator

NCT05226390Phase 1Terminated

Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate

Role: collaborator

NCT05950776Phase 2Withdrawn

COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults

Role: collaborator

NCT04895449Phase 1Completed

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19

Role: collaborator

NCT03884816Completed

HIV and STIs Clinical Study in Germany

Role: collaborator

NCT02375906Completed

The Hepatitis Delta International Network

Role: collaborator

NCT04569383Phase 1Completed

Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19

Role: collaborator

NCT03818308Phase 2Completed

Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir

Role: collaborator

NCT00908544Not ApplicableCompleted

New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients

Role: collaborator

NCT03282474Phase 2Completed

HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)

Role: collaborator

NCT03590600Phase 1Completed

A Single Ascending Dose Study of BTZ043

Role: collaborator

NCT03643172Unknown

Terminator 2 Register

Role: collaborator

NCT02704533Phase 1Completed

Sequential Optimization of Dose and Schedule of PfSPZ Vaccine

Role: collaborator

NCT02545296Not ApplicableCompleted

HIV Point-of-Care Test Evaluation in Infants

Role: collaborator